2.01
Compugen Ltd stock is traded at $2.01, with a volume of 503.83K.
It is up +1.01% in the last 24 hours and down -29.72% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
See More
Previous Close:
$1.99
Open:
$2.05
24h Volume:
503.83K
Relative Volume:
1.07
Market Cap:
$190.12M
Revenue:
$72.76M
Net Income/Loss:
$35.34M
P/E Ratio:
5.4427
EPS:
0.3693
Net Cash Flow:
$-62.91M
1W Performance:
-1.47%
1M Performance:
-29.72%
6M Performance:
+33.11%
1Y Performance:
+21.82%
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CGEN
Compugen Ltd
|
2.01 | 190.12M | 72.76M | 35.34M | -62.91M | 0.3693 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Initiated | Lake Street | Buy |
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Compugen presents ovarian cancer trial poster at ESMO meeting - Investing.com UK
Compugen presents ovarian cancer trial poster at ESMO meeting By Investing.com - Investing.com Canada
Compugen spotlights COM701 ovarian trial at ESMO congress - Stock Titan
Compugen Ltd (CGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Compugen Ltd (CGEN) Institutional Confidence - TradingKey
Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions - Yahoo Finance UK
Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Compugen Ltd (CGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compugen Ltd (CGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compugen Ltd (CGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compugen Ltd (CGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Compugen Ltd (CGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Compugen Ltd (CGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CGEN Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage Continues; Stock DeclinesStrong Earnings Momentum - newsline.com
CGEN Q1 2026 Earnings: EPS Misses Estimates amid R&D FocusRevenue Beat Analysis - newsline.com
Compugen Ltd. (CGEN) Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues Development - newsline.com
Compugen Ltd (CGEN) to Present MAIA-Ovarian Trial Progress at Eu - GuruFocus
Compugen to present ovarian cancer trial poster at ESMO - Investing.com UK
Compugen to present ovarian cancer trial poster at ESMO By Investing.com - Investing.com South Africa
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 - Yahoo Finance
[EFFECT] COMPUGEN LTD SEC Filing - Stock Titan
AI cancer drug development talk with Compugen streams June 15 - Stock Titan
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development - TradingView
CGEN STOCK : PRICE RECOVERY | COMPUGEN STOCK (kbWl8ONY7V) - Fathom Journal
CGEN Q1 2026 Earnings: EPS Misses Estimates as Stock Declines on No RevenueEarnings Call Highlights - newsline.com
H.C. Wainwright reiterates Compugen stock rating on ASCO data - Investing.com UK
H.C. Wainwright reiterates Compugen stock rating on ASCO data By Investing.com - Investing.com Canada
CGEN Q1 2026 Earnings: Wider-than-Expected Loss but Early-Stage Pipeline Progress Maintains MomentumFinancial Data - newsline.com
Why The Narrative Around Compugen (NasdaqCM:CGEN) Is Shifting After Analyst Resets And New Views - Yahoo Finance
Compugen Q1 2026 Earnings Call: Complete Transcript - Benzinga
Compugen Shares Slide 5.4% as Key Support Level ApproachesGrowth Stock Picks - newsline.com
Compugen (CGEN) Drops Nearly 4% as Stock Tests Key Support LevelsUndervalued Stocks - The Legal Advocate
Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN) - MSN
Earnings Preview: Compugen to Report Financial Results Pre-market on May 18 - Moomoo
Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Compugen Ltd (CGEN) Stock Price, Trades & News - GuruFocus
Compugen (CGEN) Surges 7.28% as Shares Approach Key Resistance LevelBull Pennant - The Legal Advocate
Compugen Surges 7% as Biotech Stock Tests Key Resistance Levels (CGEN)Positive Gamma - thelegaladvocate.com
Compugen Ltd. Q1 2026 Earnings: Narrowing Losses but Misses EstimatesHot Momentum Watchlist - Newser
Compugen Q1 2026 earnings preview - MSN
Compugen Ltd. (CGEN) Q1 2026 Earnings: Earnings Miss Slightly but Shares Rally on Upcoming CatalystGuidance Update - Newser
CGEN Q1 2026 Earnings: EPS Misses Estimates but Stock Rises 7.28% on Pipeline ProgressOne-Time Loss Impact - newsline.com
Leerink Partners Maintains Compugen(CGEN.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
CGEN Maintains Outperform Rating -- Price Target Lowered to $5.0 - GuruFocus
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):